Ladenburg Thalmann Financial Services’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Buy	+6	New	+$5	﹤0.01%	5708
2019 Q2	–	Sell	-6	Closed	–	–	5581
2019 Q1	$0	Hold	6	–	–	﹤0.01%	5472
2018 Q4	$0	Buy	+6	New	+$25	﹤0.01%	5467
2016 Q2	–	Sell	-647	Closed	-$12K	–	4915
2016 Q1	$12K	Sell	647 -3	-0.5%	-$58	﹤0.01%	3619
2015 Q4	$17K	Buy	650 +3	+0.5%	+$104	﹤0.01%	3356
2015 Q3	$29K	Hold	647	–	–	﹤0.01%	2857
2015 Q2	$21K	Hold	647	–	–	﹤0.01%	3221
2015 Q1	$21K	Hold	647	–	–	﹤0.01%	3170
2014 Q4	$24K	Hold	647	–	–	﹤0.01%	2883
2014 Q3	$17K	Buy	+647	New	+$17.1K	﹤0.01%	2799

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PFO

Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ladenburg Thalmann Financial Services's NAVB Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services opened a new position in Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2019: 6 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #5708 among its holdings. This is a return to the name: Ladenburg Thalmann Financial Services previously reported a position in NAVB as recently as Q1 2019.

Ladenburg Thalmann Financial Services first reported a position in NAVB in Q3 2014 and has held it in 10 quarters since. The position peaked at $29K in Q3 2015. 28 funds tracked by Wall St. Rank hold NAVB as of Q4 2019.

Ladenburg Thalmann Financial Services held 6 shares of Navidea Biopharmaceuticals Inc. worth $0 as of Q4 2019.
Navidea Biopharmaceuticals Inc. was a new Ladenburg Thalmann Financial Services position in Q4 2019.
Navidea Biopharmaceuticals Inc. made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5708 holding.
Ladenburg Thalmann Financial Services first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2014 and has held it in 10 quarters since.
Ladenburg Thalmann Financial Services's Navidea Biopharmaceuticals Inc. position peaked at $29K in Q3 2015.
28 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.